Mark Deeg
About Mark Deeg
Mark Deeg serves as the Executive Vice President of Global Clinical Development at Cullgen Inc., where he has worked since June 2021. He holds both an M.D. and a Ph.D., and has extensive experience in leading clinical development programs across various therapeutic areas.
Work at Cullgen
Mark Deeg serves as the Executive Vice President of Global Clinical Development at Cullgen Inc. since June 2021. In this role, he is responsible for overseeing clinical development initiatives that span various therapeutic areas. His leadership contributes to the advancement of clinical programs from preclinical studies through proof-of-concept and phase 2 trials. Based in San Diego, California, he plays a pivotal role in shaping the global clinical development strategy for the organization.
Education and Expertise
Mark Deeg holds both an M.D. and a Ph.D., having studied Pharmacology and Medicine at the University of Minnesota from 1981 to 1988. He completed his Internal Medicine Residency at Case Western Reserve University School of Medicine from 1988 to 1992 and further specialized in Endocrinology, Diabetes, and Metabolism at the University of Washington from 1992 to 1995. His extensive education underpins his expertise in clinical development across diverse therapeutic areas.
Background
Mark Deeg has a diverse professional background in clinical development and medical research. He began his career at Indiana University as an Associate Professor from 1995 to 2006. He then joined Eli Lilly and Company, where he worked as a Research Physician from 2006 to 2013 and later as Senior Medical Director and Chief Medical Officer for Chorus from 2013 to 2017. After his tenure at Eli Lilly, he served as Chief Medical Officer at Regulus Therapeutics from 2017 to 2018.
Previous Positions
Before joining Cullgen, Mark Deeg held several significant roles in the biotechnology and pharmaceutical sectors. At Pear Therapeutics, he served as Vice President of Research and Development from 2020 to 2021 and as Vice President of Discovery and Translational Research for a brief period in 2019. His experience also includes leadership positions at Regulus Therapeutics, where he was Chief Medical Officer and Vice President of Translational Medicine in 2017.
Clinical Development Experience
Mark Deeg has extensive experience leading clinical development programs across various therapeutic areas, including diabetes, NASH, obesity, oncology, pain, dermatology, dyslipidemia, and neuroscience. His involvement spans the entire clinical development process, from preclinical studies to proof-of-concept and phase 2 trials, demonstrating his comprehensive understanding of the clinical landscape.